Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04991935 · ClinicalTrials.gov registry record · Phase 3

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

A Phase 3 study of Eosinophilic Esophagitis, sponsored by Celgene.

Active
Registry status
Phase 3
Development phase
368
Enrollment target
20
Study locations

NCT04991935 is a Phase 3 study of Eosinophilic Esophagitis that is active but no longer recruiting, run by Celgene. The registered enrollment target is 368 participants, below the 856-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04991935, a Phase 3 study of Eosinophilic Esophagitis, is active but no longer recruiting, sponsored by Celgene.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
368 participants
Enrollment target
20
Study locations

Study Summary

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.

Conditions Studied

Eosinophilic Esophagitis

Interventions

  • DRUG CC-93538

Study Locations (20)

Florida

  • Local Institution - 099 - Clearwater
  • Local Institution - 036 - Inverness
  • Local Institution - 042 - Jacksonville
  • Local Institution - 138 - Miami
  • Local Institution - 146 - Orlando

Arizona

  • Local Institution - 082 - Phoenix
  • Local Institution - 147 - Phoenix
  • Local Institution - 041 - Scottsdale
  • Local Institution - 029 - Tucson

California

  • Local Institution - 075 - Lancaster
  • Local Institution - 047 - Los Angeles
  • Local Institution - 160 - San Diego

Colorado

  • Local Institution - 068 - Aurora
  • Local Institution - 067 - Colorado Springs
  • Local Institution - 128 - Wheat Ridge

Connecticut

  • Local Institution - 101 - Bristol
  • Local Institution - 076 - Farmington
  • Local Institution - 156 - Hamden

Alabama

  • Local Institution - 144 - Birmingham

Arkansas

  • Local Institution - 165 - North Little Rock

Trial Details

FieldValue
Enrollment Target 368 participants
Start Date 2021-09-14
Est. Completion 2026-09-29
Phase Phase 3

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04991935

The ClinicalTrials.gov registry entry for NCT04991935 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 856-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (57% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which CC-93538 is the first listed.

NCT04991935 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT04991935 about?

NCT04991935 is a clinical study titled "Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis". This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.

What is the current status of trial NCT04991935?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 368 participants. The study started on 2021-09-14. Estimated completion is 2026-09-29.

What conditions does trial NCT04991935 study?

This clinical trial studies the following conditions: Eosinophilic Esophagitis.

What interventions are being tested in trial NCT04991935?

The interventions under investigation include: CC-93538 (DRUG).

Who is sponsoring clinical trial NCT04991935?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04991935 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Eosinophilic Esophagitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Eosinophilic Esophagitis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.